Hence, these results above suggested that combination of HER2-targeted agents with NDRG1 inducer, DpdtC may achieve greater anti-tumor effects via more effectively inhibiting the phosphorylation of ERK1/2 and downstream signaling pathway. The gene discussed is ERBB2; the disease is neoplasm.